Who funds lung cancer research?

We count 43 funded lung cancer projects, active between 2021 and 2032, from 4 funders. The most came from EU · MSCA (14 projects), EU · ERC (13 projects) and EU · Health (7 projects). The median award is $2.1M, across the 41 of 43 projects that list an amount.

Funded projects

43

Funders

4

Median award

$2.1M

Open calls now

0

Top funders of lung cancer research

Projects whose title or summary mentions lung cancer. Median award: of the projects that list an amount, in US dollars; “—” when fewer than 3 do.

Open lung cancer funding calls

No open call mentions lung cancer in our listings today. We add new calls twice a day; create a free account to get an alert when one opens.

Forecast: announced, not open yet

1 forecast call on lung cancer. Funders publish forecasts before a call opens; you can't apply to these yet, and dates can change.

• ForecastSingle Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed)
  National Institutes of HealthNot specifiedExpected to open November 25, 2026

Funded lung cancer projects

A sample, latest start first, at most three per program.

• Neutrophil-fibroblast interactions – how do they alter the tumour microenvironment and influence disease progression in non-small cell lung cancer?
  Wellcome · ends 2028
• Understanding the role of indoor air pollution on lung cancer risk in never- smokers of different ethnicities: a pilot study
  Wellcome · ends 2028
• Collaborative Research: III: Small: Closing Sim-to-Real Gap in Reinforcement Learning via Randomization, Alignment, and Derivation
  NSF · CISE · $99,987 · ends 2027
• Predicting immunotherapy response in melanoma and non-small cell lung cancer patients using an extracellular vesicle-derived miRNA signature and a non-invasive CRISPR-based detection assay.
  EU · MSCA · €242,261 · 2027–2029 · CENTRE GEORGES-FRANCOIS LECLERC ASSOCIATION
• A Dual Amplification Photoelectrochemical Platform for KRAS Mutation Detection
  EU · MSCA · €216,240 · 2027–2029 · UNIVERSITEIT ANTWERPEN
• KRAS Targeting in Oncogenic Systems: reconstructing the KRAS signalling network to identify optimal drug combinations
  EU · MSCA · €426,534 · 2027–2030 · UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
• Specific delivery of active biomolecules to treat lung cancer
  EU · ERC · €3,323,826 · 2026–2031 · FUNDACIO CENTRE DE REGULACIO GENOMICA
• LUng Modeling and INtelligence for Advanced care: A Digital Twin Approach to Lung Cancer Diagnosis and Treatment
  EU · EIC · €3,998,944 · 2026–2030 · AALBORG UNIVERSITET
• TUMOUR ACTIVATED IMMUNOTHERAPY FOR SOLID TUMOURS (TAIST)
  EU · Health · €7,478,175 · 2026–2029 · ACCESSION THERAPEUTICS LIMITED
• LUMES LUng cancer Metastasis Evolutionary Studies
  EU · ERC · €11,542,341 · 2026–2032 · KUNGLIGA TEKNISKA HOEGSKOLAN

How we count

Funded projects come from public award records (NIH RePORTER, NSF, EU CORDIS, UKRI Gateway to Research, Wellcome, the Gates Foundation, DOE, NASA and USDA NIFA) whose title or summary matches “lung cancer”. NIH lists each budget year separately; one project counts once. Amounts are as the funder lists them; medians use only projects that list one, in US dollars. Open calls and forecasts are from our listings of October 28, 2026. A project can mention a topic without being mainly about it, so treat the counts as a guide to who funds the area.